Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Breastfeeding during early life reduces need for pacifiers

05 Nov 2019

Exclusive breastfeeding (EB) for the first 6 months after birth appears to reduce pacifier-sucking behaviours at 12 months of life, a recent study has found.

Researchers enrolled 1,307 infants who were followed up to 12 months of life. Breastfeeding patterns were assessed 4 and 6 months after birth. Infants were categorized into four breastfeeding types: exclusive, predominant, complementary or none. The effect of breastfeeding type on pacifier behaviours was the primary outcome.

Of the participants, majority did not use pacifiers at 12 months (n=590; 51.5 percent male); the remaining 447 did (54.1 percent male). Using month 4 observations, researchers found that infants who had been complementarily breastfed or who had not been breastfed at all were more likely to exhibit pacifier-sucking behaviours at 12 months.

The same was true for children whose breastfeeding patterns were observed at 6 months. In comparison, exclusive and predominant breastfeeding seemed to attenuate the need for pacifiers.

Logistic regression analysis found that no (adjusted relative risk [RR], 2.67, 95 percent confidence interval [CI], 2.24–3.17) and complementary (adjusted RR, 1.68, 95 percent CI, 1.39–2.02) breastfeeding for the first 4 months of life were significant risk factors for pacifier behaviours at 12 months. Risk estimates were calculated in comparison to EB.

Similarly, no (adjusted RR, 3.30, 95 percent CI, 2.40–4.54) and complementary (adjusted RR, 1.43, 95 percent CI, 1.03–2.00) breastfeeding during the first 6 months of life correlated significantly with a higher likelihood of pacifier use after 12 months.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.